文献速递贫血与红细胞疾病血栓与止血MDS 与骨髓增殖性肿瘤

衰老一般人群中外周血细胞减少与血液病及死亡风险

Peripheral blood cytopenias in the aging general population and risk of incident hematological disease and mortality.
PubMed 文献 · Blood Adv · 2021-01-01

在Lifelines队列167729名社区居住者中,研究衰老过程中外周血细胞减少的自然病程及其与血液系统疾病和死亡的关系。贫血和血小板减少随年龄增长而出现,并与较差总生存相关,尤其两者并存时风险更高;中性粒细胞减少不影响生存。仅小部分死亡归因于确诊的血液恶性肿瘤,≥60岁者5年累计血液恶性肿瘤发生率0.60%。

要点

  • 贫血和血小板减少与较差总生存相关,两者并存时风险最高。
  • 中性粒细胞减少无论孤立或合并其他血细胞减少均不影响总生存。
  • ≥60岁者5年血液恶性肿瘤累计发生率0.60%,贫血或血小板减少者更高。

核心结论

  • 贫血和血小板减少与社区居住个体较差总生存相关,中性粒细胞减少则无此关联。
  • 这些血细胞减少者中仅小部分进展为血液恶性肿瘤。

研究设计与样本

  • 基于人群的Lifelines队列研究,纳入167729名社区居住个体。
  • 通过链接全国登记系统评估血液恶性肿瘤发生和死因别死亡。

主要发现

  • 贫血与较差总生存相关(HR 1.84;95%CI 1.59-2.12)。
  • 血小板减少与较差总生存相关(HR 1.58;95%CI 1.32-1.89)。
  • 贫血合并血小板减少与较差总生存相关(HR 4.75;95%CI 2.98-7.55)。
  • 孤立性中性粒细胞减少不影响总生存(HR 0.88;95%CI 0.73-1.06)。
  • ≥60岁者5年血液恶性肿瘤累计发生率为0.60%(95%CI 0.50-0.70)。

关键数值与推荐

  • 采用标准参考范围定义血细胞减少。
  • ≥60岁个体中,贫血者(P < .001)或血小板减少者(P < .001)血液恶性肿瘤累计发生率更高,中性粒细胞减少者无显著差异(P = .201)。

临床怎么用

  • 对老年贫血或血小板减少患者应关注总生存风险,尤其两者并存时。
  • 中性粒细胞减少对总生存影响不明显,但仍需结合临床评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Peripheral blood cytopenias may precede the development of hematological malignancies and frequently pose clinical challenges in the older population. The natural course of (mild) cytopenias during aging and their association with hematological disorders in community-dwelling individuals are not well studied. Within the population-based Lifelines cohort (n = 167729), we studied changes in peripheral blood counts, occurrence of cytopenias, and associated hematological outcomes in the context of aging. Development of hematological malignancies and (cause-specific) mortality were evaluated by linkage to nationwide registries. Anemia and thrombocytopenia emerged with older age, in line with a general age-related decline in these blood counts. For neutropenia, no increase in prevalence with older age was observed. Using standard reference limits to define cytopenias, anemia (hazard ratio [HR], 1.84; 95% confidence interval [CI], 1.59-2.12), thrombocytopenia (HR, 1.58; 95% CI, 1.32-1.89), and, especially the concomitant presence of anemia and thrombocytopenia (HR, 4.75; 95% CI, 2.98-7.55) were associated with inferior overall survival. Only a minor proportion of deaths was explained by diagnosed hematological malignancies, with the majority attributable to other causes. Neutropenia, either isolated (HR, 0.88; 95% CI, 0.73-1.06) or combined with another cytopenia, did not affect overall survival. For individuals aged ≥60 years, 5-year cumulative incidence of hematological malignancies was 0.60% (95% CI, 0.50-0.70), with higher incidences among those with anemia (P < .001) or thrombocytopenia (P < .001) but not neutropenia (P = .201). Highest cumulative incidences of diagnoses and mortality from hematological malignancies were observed in individuals with >1 cytopenia. We conclude that anemia and thrombocytopenia, but not neutropenia, are associated with inferior overall survival of community-dwelling individuals. Hematological malignancies develop in a small fraction of these cases.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. van Zeventer IA, de Graaf AO, van der Klauw MM, et al. Peripheral blood cytopenias in the aging general population and risk of incident hematological disease and mortality. Blood Adv. 2021. PMID: 34459888. doi:10.1182/bloodadvances.2021004355

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。